Results

Total Results: 376 records

Showing results for "renal".

141. Methods White Paper: Improving the Utility of Evidence Synthesis for Decision Makers in the Face of Insufficient Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/improving-utility-evidence-synthesis-white-paper.pdf
     April 01, 2021 - Denervation in the Medicare Population35 What is the evidence for renal denervation effectiveness … Management of Renal Masses and Localized Renal Cancer36 Efficacy and comparative efficacy of different … interventions for the management of a renal mass suspicious for localized renal cell carcinoma … Renal denervation in the medicare population. … Management of renal masses and localized renal cancer: systematic review and meta- analysis.

142. Chronic-urinary-retention-protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-urinary-retention_research-protocol.pdf
     November 19, 2012 - effort to do so.1 AUR typically is associated with lower abdominal pain and may lead to infection, renal … Commonly performed tests include: • urinalysis (UA) • urine culture • measures of renal function … • renal

143. Nonopioid Pharmacologic Treatments for Chronic Pain: Appendix F2 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/nonopioid-chronic-pain-apf2_0.xlsx
     January 01, 2018 - Events CV Events GI GI GI GI Liver Dysfunction Liver Dysfunction Liver Dysfunction Liver Dysfunction Renal … Dysfunction Renal Dysfunction Renal Dysfunction Renal Dysfunction Application Site Reaction (additional … Events CV Events GI GI GI GI Liver Dysfunction Liver Dysfunction Liver Dysfunction Liver Dysfunction Renal … Dysfunction Renal Dysfunction Renal Dysfunction Renal Dysfunction Application Site Reaction (additional

144. Diabetes-Foot-Ulcer-Amputation-Prevalence Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-foot-ulcer-amputation-prevalence_research.pdf
     February 01, 2011 - Those with diabetes are expected to suffer from several associ- ated medical complications, such as renal … The prevalence of LEA in nonelderly diabetics with PAD (many of whom likely have end-stage renal disease

145. CER 173 Executive Summary: Diabetes Medications for Adults With Type 2 Diabetes: An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_executive.pdf
     January 01, 2015 - pressure and heart rate, and for studies that include a comparison with SGLT-2 inhibitors, impaired renal … • We included studies addressing the following safety outcomes for KQ3: – Liver injury – Impaired renal … The exclusion criteria were generally similar for most trials: significant renal, cardiovasular, and … described in prior reviews.18, 68 The evidence on SGLT-2 inhibitor comparisons regarding fractures, renal … Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes

146. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-atrial-fibrillation_research-protocol.pdf
     January 30, 2012 - coronary syndrome o Subpopulations, including: patients with comorbid conditions, such as dementia, or renal … Subgroups of potential interest include: o Patients who have comorbid conditions such as dementia or renal … Food and Drug Administration; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding … Food and Drug Administration GWTG Get With The Guidelines HAS-BLED hypertension, abnormal renal/liver

147. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/angina-heart-attack-treatments_research-protocol.pdf
     December 11, 2012 - percent being cleared by the kidneys, and has a plasma half-life of 25 minutes in patients with normal renal … disease:  Subgroups by age, sex, weight, body mass index, diabetes, heart failure, previous stroke, renal … characteristics • Age • Sex • Diabetes • Weight • Body mass index • Heart failure • Previous stroke • Renal … characteristics including age, sex, weight, body mass index, diabetes, heart failure, previous stroke, renal … minutes and then continued at 0.1 mcg/kg/min for 12 to 24 hr following PCI Patients with severe renal

148. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1512.pdf
     December 29, 2015 - organic anion transporter involved in controlling the reabsorption of uric acid from the proximal renal … Use of lesinurad alone resulted in more patients experiencing elevated serum creatinine levels and renal … , diarrhea, and nausea.27 Some preliminary evidence suggests lesinurad could increase the risk of renal … However, better gout management could reduce hospitalizations and renal or cardiovascular complications … provide cost offsets from treatment with lesinurad.38,40 Two research experts noted concerns over renal

149. Vitamin-D-Calcium-Protocol-130611 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/vitamin-d-calcium_research-protocol.pdf
     September 13, 2013 - cardiovascular diseases, cancer, immune function, pregnancy or birth outcomes, mortality, fracture, renal … Adverse effects of intervention(s)  All-cause mortality  Cancer and cancer-specific mortality  Renal … upper intake levels (ULs/AEs; specifically, all-cause mortality; cancer and cancer-specific mortality, renal

150. Systematic Review of Calcineurin Inhibitors for Kidney Transplant | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/calcineurin-inhibitor/research-protocol

151. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dietary-supplements_research-protocol.pdf
     December 15, 2010 - Syncope • Quality of life • Hospitalization • Adherence to prescribed cardiovascular drug regimen • Renal … aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], or hepatitis) o Renal … disease, with known cardiovascular disease; participants with diabetes; participants with hepatic or renal … dysfunction or end-stage renal disease; participants taking a cardiovascular drug for an indication … adverse events, clinical bleeding (intracranial, gastrointestinal, genitourinary, subretinal, etc.), renal

152. Screening for and Management of Chronic Kidney Disease Stages 1-3 | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/kidney-disease-medicine/research-protocol

153. Dietary-Supplements Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_executive.pdf
     April 01, 2012 - .); renal dysfunction (e.g., proteinuria, elevated creatinine, need for transplant, glomerular filtration … fatty acids (3 or 6 g/day) + Warfarin Vitamin E (400 IU/day) + ASA Vitamin K (5 mg/day) + Warfarin Renal … bias for the gradable outcomes of harms (serious adverse events, withdrawal due to adverse events, renal … No statistically significant differences were observed for withdrawal due to adverse events,42,73 renal … collect data and undertake subgroup analysis for age, gender, race, comorbidities (e.g., liver or renal

154. Disposition of Comments Report for Treatment for Hepatitis C Virus Infection in Adults (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c_disposition-comments.pdf
     November 27, 2012 - treatment-naive individuals and does not consider "difficult-to-treat" populations (e.g., HIV- coinfected, renal … Treatment decisions for HIV-coinfected patients and persons with end- stage renal disease might differ … not aware of trials of antiviral treatments that have specifically enrolled patients with end-stage renal … Additional CERs of treatments in HIV-coinfected patients, patients with end-stage renal disease, and … Additional CERs of treatments in HIV-coinfected patients, patients with end-stage renal disease, and

155. Rheumatoid-Arthritis-Medicine Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-medicine_executive.pdf
     April 01, 2012 - Toxicity was more likely with MTX in patients with greater renal impairment. … Those with high- risk comorbidities (cardiovascular events, diabetes, malignancies, renal impairment

156. Disposition of Comments CER 214 Stroke Prevention in Patients With Atrial Fibrillation (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-214-afib-disposition-comments.pdf
     October 30, 2019 - At least at higher (non-renal) doses the effects look quite similar and I'm not sure it makes sense … Preventing Thromboembolic Events The evidence indicates that the interplay of DOAC dosing and renal … We do however explore patients with renal impairement as a specific subgroup of interest and summarize … to ≤ 95 mL/min, while 30 mg once-daily dose of edoxaban is approved to treat NVAF in patients with renal … At least at higher (non-renal) doses the effectiveness looks quite similar.

157. Disposition of Comments Report for Enzyme-Replacement Therapies for Lysosomal Storage Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/lysosomal-storage-diseases-therapies_disposition-comments.pdf
     January 01, 2014 - Outcomes varied by study, including plasma substrate level, renal function, cerebrovascular disease … Outcomes varied by study, including plasma substrate level, renal function, cerebrovascular disease … ERT has been shown to stabilize or slow the decline of renal function in patients with Fabry disease … (Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease … Renal or cardiac function outcomes were investigated in six clinical studies of patients with Fabry

158. Executive summary_Comparative Effectiveness Review No. 264_Social and Structural Determinants of Maternal Morbidity and Mortality: An Evidence Map (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-264-maternal-morbidity-mortality-executive-summary.pdf
     December 01, 2023 - by comorbidities (including prepregnancy body mass index, diabetes, hypertension, cardiac disease, renal

159. Geographic Variation in Carotid Endarterectomy and Carotid Stenting Among Medicare Beneficiaries, 2003-2006 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cardiology-health-outcomes_research.pdf
     July 01, 2010 - 290.x, 294.1, and 331.2), diabetes mellitus (code 250), hypertension (codes 401-405 and 437.2), and renal … Hypertension — 60 418 (90.6) 6820 (92.7) Peripheral vascular disease — 24 625 (36.9) 3386 (46.0) Renal … 1.35-1.39)b 1.58 (1.52-1.64)b Previous carotid endarterectomy 1.12 (1.05-1.20)c 3.06 (2.65-3.53)b Renal

160. Sodium and Potassium Intake: Effects on Chronic Disease Outcomes and Risks | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/sodium-potassium/final-report-2018